Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Conditions Studied
Interventions
- DRUG FG-3246
Study Locations (15)
California
- UCLA Clark Urology Center — Los Angeles
- University of California San Francisco — San Francisco
Florida
- Bioresearch Partner — Aventura
- Bioresearch Partner — Hialeah
North Carolina
- UNC Hospitals, The University of North Carolina at Chapel Hill — Chapel Hill
- Duke University Medical Center - Duke Cancer Center — Durham
Texas
- University of Texas Southwestern Medical Center — Dallas
- Oncology Consultants — Houston
Arizona
- The University of Arizona Cancer Center - North Campus — Tucson
Georgia
- Winship Cancer Institute, Emory University — Atlanta
New Mexico
- New Mexico Oncology Hematology Consultants, Ltd. — Albuquerque
Ohio
- University Hospitals Cleveland Medical Center — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-02-22 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06842498
The ClinicalTrials.gov registry entry for NCT06842498 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention — of which FG-3246 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06842498 reports 15 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06842498 about?
NCT06842498 is a clinical study titled "A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second...
What is the current status of trial NCT06842498?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-02-22. Estimated completion is 2028-03-31.
What conditions does trial NCT06842498 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06842498?
The interventions under investigation include: FG-3246 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06842498?
This trial is sponsored by Kyntra Bio, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06842498 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Georgia, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.